The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: A phase 1B dose-expansion study.
 
Junjie Gu
No Relationships to Disclose
 
Lili Mao
Honoraria - MSD; Novartis; Shanghai Junshi BioSciences
Research Funding - MSD
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Yu Jiang
No Relationships to Disclose
 
Lingjun Zhu
No Relationships to Disclose
 
Xiaoshi Zhang
No Relationships to Disclose
 
Wangjun Yan
No Relationships to Disclose
 
Yu Chen
No Relationships to Disclose
 
Chang Tan
No Relationships to Disclose
 
Weiyou Zhu
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Jie Liu
No Relationships to Disclose
 
Jing Lin
No Relationships to Disclose
 
Zhuli Wu
No Relationships to Disclose
 
Xingli Wang
No Relationships to Disclose
 
Yuchen Yang
No Relationships to Disclose
 
Ben Li
No Relationships to Disclose
 
Lu Si
No Relationships to Disclose